TY - JOUR
T1 - Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1
AU - Gorny, Miroslaw K.
AU - Williams, Constance
AU - Volsky, Barbara
AU - Revesz, Kathy
AU - Wang, Xiao Hong
AU - Burda, Sherri
AU - Kimura, Tetsuya
AU - Konings, Frank A.J.
AU - Nádas, Arthur
AU - Anyangwe, Christopher A.
AU - Nyambi, Phillipe
AU - Krachmarov, Chavdar
AU - Pinter, Abraham
AU - Zolla-Pazner, Susan
PY - 2006/7
Y1 - 2006/7
N2 - The majority of global human immunodeficiency virus infections are caused by viruses characterized by a GPGQ motif at the tip of the V3 loop. Characterization of anti-V3 monoclonal antibodies (MAbs) that neutralize isolates with the GPGQ V3 motif is an important step in designing vaccines that will induce such Abs. Consequently, seven human anti-V3 MAbs derived from the cells of individuals infected with non-B-subtype viruses (anti-V3 non-B MAbs) were generated from the cells of individuals from Africa infected with circulating recombinant forms CRF02_AG, CRF09_cpx, and CRF13_cpx, each of which contains a subtype A env gene. Sequence analysis of plasma viruses revealed a GPGQ motif at the apex of the V3 loop from six of the seven subjects and a GPGR motif from one subject. The MAbs were selected with fusion proteins (FP) containing V392UG037.8 or V3JR-CSF from subtype A or B, respectively. In virus binding assays, five of the seven (71%) anti-V3 non-B MAbs bound to V3-FPs from both subtype A and subtype B, while only four of the nine (44%) anti-V3B MAbs recognized both V3-FPs. Using two neutralization assays, both the anti-V3non-B and the anti-V3B MAbs neutralized subtype B viruses with similar activities, while the anti-V3non-B MAbs exhibited a tendency toward both increased potency and breadth of neutralization against non-B viruses compared to anti-V3B MAbs. Statistical significance was not achieved, due in large measure to the sizes of the MAb panels, but the overall pattern of data strongly suggests that viruses with the GPGQ motif at the tip of the V3 loop induce anti-V3 Abs with broader cross-neutralizing activity than do viruses with the GPGR motif.
AB - The majority of global human immunodeficiency virus infections are caused by viruses characterized by a GPGQ motif at the tip of the V3 loop. Characterization of anti-V3 monoclonal antibodies (MAbs) that neutralize isolates with the GPGQ V3 motif is an important step in designing vaccines that will induce such Abs. Consequently, seven human anti-V3 MAbs derived from the cells of individuals infected with non-B-subtype viruses (anti-V3 non-B MAbs) were generated from the cells of individuals from Africa infected with circulating recombinant forms CRF02_AG, CRF09_cpx, and CRF13_cpx, each of which contains a subtype A env gene. Sequence analysis of plasma viruses revealed a GPGQ motif at the apex of the V3 loop from six of the seven subjects and a GPGR motif from one subject. The MAbs were selected with fusion proteins (FP) containing V392UG037.8 or V3JR-CSF from subtype A or B, respectively. In virus binding assays, five of the seven (71%) anti-V3 non-B MAbs bound to V3-FPs from both subtype A and subtype B, while only four of the nine (44%) anti-V3B MAbs recognized both V3-FPs. Using two neutralization assays, both the anti-V3non-B and the anti-V3B MAbs neutralized subtype B viruses with similar activities, while the anti-V3non-B MAbs exhibited a tendency toward both increased potency and breadth of neutralization against non-B viruses compared to anti-V3B MAbs. Statistical significance was not achieved, due in large measure to the sizes of the MAb panels, but the overall pattern of data strongly suggests that viruses with the GPGQ motif at the tip of the V3 loop induce anti-V3 Abs with broader cross-neutralizing activity than do viruses with the GPGR motif.
UR - http://www.scopus.com/inward/record.url?scp=33745785048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745785048&partnerID=8YFLogxK
U2 - 10.1128/JVI.02202-05
DO - 10.1128/JVI.02202-05
M3 - Article
C2 - 16809292
AN - SCOPUS:33745785048
SN - 0022-538X
VL - 80
SP - 6865
EP - 6872
JO - Journal of virology
JF - Journal of virology
IS - 14
ER -